2026 ICD-10-CM Diagnosis Code E16.8Other specified disorders of pancreatic internal secretion

ICD-10-CM Codes›E00–E89›E15-E16›E16

ICD-10-CM E16.8
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E16.8 is a billable ICD-10-CM diagnosis code for other specified disorders of pancreatic internal secretion. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 643 through 645. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified endocrine disorders.

Code Identity

ICD-10-CM Code
E16.8
Billable Status
Yes — Valid for Submission
Code Describes
Other specified disorders of pancreatic internal secretion
Short Description
Other specified disorders of pancreatic internal secretion
Same as the full description in the CMS dataset.
Parent Code
E16
Other disorders of pancreatic internal secretion

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE15-E16Other disorders of glucose regulation and pancreatic internal secretion
CategoryE16Other disorders of pancreatic internal secretion
This CodeE16.8Other specified disorders of pancreatic internal secretion

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Abnormal hormone secretion
  • Abnormality of bombesin secretion
  • Abnormality of cholecystokinin-pancreozymin secretion
  • Abnormality of gastric inhibitory peptide secretion
  • Abnormality of glicentin secretion
  • Abnormality of motilin secretion
  • Abnormality of pancreatic polypeptide secretion
  • Abnormality of secretin secretion
  • Abnormality of secretion of gastrin
  • Abnormality of secretion of glucagon
  • Abnormality of somatostatin secretion
  • Abnormality of vasoactive intestinal peptide secretion
  • Diminished gastrin secretion
  • Excessive bombesin secretion
  • Excessive cholecystokinin-pancreozymin secretion
  • Excessive gastric inhibitory peptide secretion
  • Excessive glicentin secretion
  • Excessive motilin secretion
  • Excessive pancreatic polypeptide secretion
  • Excessive secretin secretion
  • Excessive somatostatin secretion
  • Glucagon deficiency
  • Hypoinsulinemic hypoglycemia and body hemihypertrophy
  • Hypoinsulinism
  • Neonatal hypoglycemia
  • Non-diabetic disorder of endocrine pancreas
  • Verner-Morrison syndrome

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Increased secretion from endocrine pancreas of growth hormone-releasing hormone
  • Increased secretion from endocrine pancreas of pancreatic polypeptide
  • Increased secretion from endocrine pancreas of somatostatin
  • Increased secretion from endocrine pancreas of vasoactive-intestinal polypeptide

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Disorder(of)
      • pancreatic internal secretion
        • specified NEC
    • Hyperplasia, hyperplastic
      • pancreatic islet cells
        • alpha
    • Increase, increased
      • secretion
        • pancreas, endocrine
          • growth hormone-releasing hormone
    • Increase, increased
      • secretion
        • pancreas, endocrine
          • pancreatic polypeptide
    • Increase, increased
      • secretion
        • pancreas, endocrine
          • somatostatin
    • Increase, increased
      • secretion
        • pancreas, endocrine
          • vasoactive-intestinal polypeptide

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END015
Other specified and unspecified endocrine disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Neonatal Hypoglycemia

    blood glucose concentration below the lower limit of established reference ranges in a newborn.

  • Glucagon Deficiency

    impaired pancreatic secretion of glucagon that results in severely low blood glucose.

Patient EducationClinical

Pancreatic Diseases

The pancreas is a gland behind your stomach and in front of your spine. It produces juices that help break down food and hormones that help control blood sugar levels. Problems with the pancreas can lead to many health problems. These include:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E16.8 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
251.8 Pancreatic disorder NEC
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E16.8Overview

Is E16.8 (Other disorders of pancreatic internal secretion) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other specified disorders of pancreatic internal secretion on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does E16.8 group to?

When other specified disorders of pancreatic internal secretion is the principal diagnosis on an inpatient stay, it groups to MS-DRG 643, 644, 645, with relative weights from 0.7683 to 1.6461 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of E16.8?

Under the General Equivalence Mappings, other specified disorders of pancreatic internal secretion converts to ICD-9-CM 251.8 (pancreatic disorder NEC). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.